Bioject Announces Hiring of President and Chief Executive Officer.

PORTLAND, Ore. -- Bioject Medical Technologies Inc. (Nasdaq:BJCT), a leading developer of needle-free drug delivery systems, today announced that it has hired Mr. Ralph Makar as President and Chief Executive Officer, effective October 1, 2007.

"We are very fortunate to have such a seasoned pharmaceutical veteran join the Bioject team," said Jerald S. Cobbs, Bioject's Chairman. "Mr. Makar's experience with specialty pharmaceuticals will add value to the Company, and help us implement a new direction and focus going forward. Our technology adds value to every injectable we deliver, and we look forward to working with strategic partners to demonstrate this added value by providing effective delivery systems to patients and professionals alike."

With a history of adding significant long-term value in the form of innovative life cycle management strategies for pharmaceutical brands, such as Betaseron[R] Injectable, Diovan[R], and others, Mr. Makar said, "I am highly enthusiastic about the prospects of bringing significant added value to patients and all stakeholders by leveraging the highly regarded benefits of Bioject's proprietary needle-free technology with injectable therapies."

Mr. Makar brings to Bioject over 20 years of strategic leadership and marketing expertise, having worked with biotech, specialty and niche pharmaceutical companies. Mr. Makar served as Vice President and General Manager of the Therapeutics Business Unit at Berlex Labs, the U.S. Division of Schering AG. He also served as Vice President of Marketing for the Therapeutics Business Unit at Berlex. Prior to joining Berlex, Mr. Makar held a number of strategic and tactical marketing positions with increasing responsibility at Novartis and Parke-Davis. Mr. Makar earned a B.S. in Pharmacy from Rutgers College of Pharmacy in Piscataway, New Jersey and an M.B.A. from Columbia Business School in New York, New York.

Bioject Medical Technologies Inc., based in Portland, Oregon, is an innovative developer and manufacturer of needle-free drug delivery systems. Needle-free injection works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid, penetrating the skin and depositing medication in the tissue beneath. The Company is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies.

For more information on Bioject, visit www.bioject.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Bioject's expectations with respect to future relationships with strategic partners. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks, uncertainties and other factors include, without limitation, the risk that the Company's products will not be accepted by the market, the risk that the Company will be unable to successfully develop and negotiate new strategic relationships or maintain existing relationships, uncertainties related to the time required for the Company to complete research and development, obtain necessary clinical data and government clearances, and the risk that the Company may be unable to comply with the extensive government regulations applicable to Bioject's business. Readers of this press release are referred to the Company's filings with the Securities and Exchange Commission, including the Company's reports on Form 10-K and Forms 10-Q for further discussions of factors that could affect the Company's business and its future results. Forward-looking statements are based on the estimates and opinions of management on the date the statements are made. The Company assumes no obligation to update forward-looking statements if conditions or management's estimates or opinions should change.